8-K: Edwards Lifesciences Reports Strong Fourth Quarter, TMTT Sales Soar 88%

Edwards Lifesciences announces better-than-expected Q4 results with 9% sales growth and significant gains in TMTT, while reiterating its 2025 outlook.

Summary

• Edwards Lifesciences reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 sales increased by 9% to $1.39 billion, exceeding expectations.
• TAVR sales grew by 6% in Q4, or 5% on a constant currency basis, reaching $1.04 billion.
• TMTT sales saw substantial growth of 88% in Q4, reaching $105 million.
• The company's Q4 EPS was $0.58, with an adjusted EPS of $0.59.
• Full-year 2024 TAVR sales reached $4.1 billion, a 6% increase year-over-year.
• Full-year TMTT sales were $352 million, up 78% year-over-year.
• The company is reiterating its 2025 constant currency sales growth guidance of 8% to 10% and adjusted EPS of $2.40 to $2.50.
• Edwards anticipates U.S. approval for asymptomatic TAVR indication by mid-year.
• The company expects increasing contributions from structural heart therapies in 2026 and beyond.
• For the first quarter of 2025, Edwards projects total sales between $1.35 and $1.43 billion and adjusted EPS of $0.58 to $0.64.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in key segments and reiteration of financial guidance. While there are some increases in expenses, the overall tone is optimistic and confident.

Positives

• Q4 sales exceeded expectations, growing 9% to $1.39 billion.
• TMTT sales demonstrated substantial growth, increasing 88% to $105 million in Q4.
• The company's adjusted EPS for Q4 was $0.59, driven by strong top-line performance.
• Edwards is reiterating its 2025 constant currency sales growth of 8% 10% and adjusted EPS of $2.40 $2.50.
• The company anticipates mid-year approval for asymptomatic TAVR indication in the U.S.
• Surgical sales increased 6% over the prior year, or 5% on a constant currency basis.
• Cash and cash equivalents were approximately $3.0 billion as of Dec. 31, 2024.

Negatives

• The gross profit margin decreased to 78.9% in Q4 2024 from 80.2% in the same period last year.
• Selling, general, and administrative expenses increased to $492 million in Q4 2024 from $417 million in the prior year.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Factors that could cause actual results to differ include risks detailed in the company's filings with the SEC.

Future Outlook

Edwards Lifesciences anticipates continued growth, driven by TAVR, Mitral and Tricuspid therapies, and emerging opportunities in Structural Heart Failure and Aortic Regurgitation, with a constant currency sales growth of 8% to 10% and adjusted EPS of $2.40 to $2.50 for 2025.

Management Comments

• Bernard Zovighian, Edwards CEO, stated that 2024 was a year of meaningful progress and that the company exited the year in a strong position with three important growth drivers: TAVR, Mitral and Tricuspid, and two emerging opportunities in Structural Heart Failure and Aortic Regurgitation.
• Mr. Zovighian is optimistic about the tremendous opportunities in front of the company to transform structural heart patient care.

Industry Context

Edwards Lifesciences' focus on structural heart innovations aligns with the growing demand for minimally invasive cardiac procedures. The company's strong performance in TAVR and TMTT reflects the increasing adoption of these therapies as alternatives to traditional open-heart surgery.

Comparison to Industry Standards

• Medtronic and Abbott are key competitors in the structural heart market.
• Edwards' TMTT growth rate of 88% significantly outpaces the overall market growth for mitral and tricuspid therapies, suggesting strong market share gains.
• The EARLY TAVR trial results position Edwards favorably compared to competitors who have not yet demonstrated similar outcomes in asymptomatic patients.

Stakeholder Impact

• Shareholders can expect continued growth and profitability based on the company's outlook.
• Employees are contributing to the advancement of life-saving structural heart innovations.
• Patients will benefit from expanded treatment options and improved clinical outcomes.
• Clinicians will have access to innovative technologies and clinical evidence to enhance patient care.

Next Steps

• The company will host a conference call to discuss the fourth quarter results.
• Edwards will continue to work closely with the FDA on expanding the labeled indication to include asymptomatic severe AS patients.
• The company looks forward to European approval of SAPIEN M3 by mid-year 2025.

Key Dates